These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23228159)

  • 21. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.
    Zhang Y; Chen M; Chen J; Wu Z; Yu S; Fang Y; Zhang C
    Psychopharmacology (Berl); 2014 May; 231(10):2211-8. PubMed ID: 24448899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender differences in C-reactive protein and homocysteine modulation of cognitive performance and real-world functioning in bipolar disorder.
    Sanchez-Autet M; Arranz B; Safont G; Sierra P; Garcia-Blanco A; de la Fuente L; Garriga M; García-Portilla MP
    J Affect Disord; 2018 Mar; 229():95-104. PubMed ID: 29306698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between metabolic syndrome, cardiometabolic risk factors and inflammatory markers in a Tehranian population: the Tehran Lipid and Glucose Study.
    Zarkesh M; Faam B; Daneshpour MS; Azizi F; Hedayati M
    Intern Med; 2012; 51(24):3329-35. PubMed ID: 23257516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of prevalence of metabolic syndrome in bipolar disorder and schizophrenia from North India.
    Grover S; Nebhinani N; Chakrabarti S; Avasthi A; Kulhara P; Basu D; Mattoo SK; Malhotra S
    Nord J Psychiatry; 2014 Jan; 68(1):72-7. PubMed ID: 23293896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up.
    Nyboe L; Vestergaard CH; Moeller MK; Lund H; Videbech P
    Schizophr Res; 2015 Oct; 168(1-2):381-7. PubMed ID: 26278336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
    Chue P; Mandel FS; Therrien F
    Curr Med Res Opin; 2014 Jun; 30(6):997-1005. PubMed ID: 24568177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-reactive protein is elevated in schizophrenia.
    Dickerson F; Stallings C; Origoni A; Vaughan C; Khushalani S; Yang S; Yolken R
    Schizophr Res; 2013 Jan; 143(1):198-202. PubMed ID: 23218564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model.
    Levine J; Sela BA; Osher Y; Belmaker RH
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Sep; 29(7):1181-91. PubMed ID: 16115716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated triglycerides are associated with decreased executive function among adolescents with bipolar disorder.
    Naiberg MR; Newton DF; Collins JE; Dickstein DP; Bowie CR; Goldstein BI
    Acta Psychiatr Scand; 2016 Sep; 134(3):241-8. PubMed ID: 27329743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder.
    Fiedorowicz JG; Palagummi NM; Forman-Hoffman VL; Miller DD; Haynes WG
    Ann Clin Psychiatry; 2008; 20(3):131-7. PubMed ID: 18633739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression - associations with mortality and psychiatric outcomes: a population-based study.
    Horsdal HT; Köhler-Forsberg O; Benros ME; Gasse C
    Eur Psychiatry; 2017 Jul; 44():164-172. PubMed ID: 28645055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism.
    Misiak B; Łaczmański Ł; Słoka NK; Szmida E; Piotrowski P; Loska O; Ślęzak R; Kiejna A; Frydecka D
    Psychiatry Res; 2016 Apr; 238():60-67. PubMed ID: 27086212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Blanca-Tamayo M
    Eur Psychiatry; 2013 Mar; 28(3):161-7. PubMed ID: 21964485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gestational maternal C--reactive protein and risk of bipolar disorder among young individuals in a Nationwide Birth Cohort.
    Chudal R; Sourander A; Surcel HM; Sucksdorff D; Hinkka-Yli-Salomäki S; Brown AS
    J Affect Disord; 2017 Jan; 208():41-46. PubMed ID: 27744125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder--Gender and obesity effects.
    Bengesser SA; Lackner N; Birner A; Fellendorf FT; Platzer M; Mitteregger A; Unterweger R; Reininghaus B; Mangge H; Wallner-Liebmann SJ; Zelzer S; Fuchs D; McIntyre RS; Kapfhammer HP; Reininghaus EZ
    J Affect Disord; 2015 Feb; 172():367-74. PubMed ID: 25451439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study.
    Birkenaes AB; Opjordsmoen S; Brunborg C; Engh JA; Jonsdottir H; Ringen PA; Simonsen C; Vaskinn A; Birkeland KI; Friis S; Sundet K; Andreassen OA
    J Clin Psychiatry; 2007 Jun; 68(6):917-23. PubMed ID: 17592917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort.
    Godin O; Etain B; Henry C; Bougerol T; Courtet P; Mayliss L; Passerieux C; Azorin JM; Kahn JP; Gard S; Costagliola D; Leboyer M;
    J Clin Psychiatry; 2014 Oct; 75(10):1078-85; quiz 1085. PubMed ID: 25373115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders.
    Vargas HO; Nunes SO; Barbosa DS; Vargas MM; Cestari A; Dodd S; Venugopal K; Maes M; Berk M
    Life Sci; 2014 Apr; 102(1):65-71. PubMed ID: 24607777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.
    Popović I; Ravanić D; Janković S; Milovanović D; Folić M; Stanojević A; Nenadović M; Ilić M
    Srp Arh Celok Lek; 2015; 143(11-12):712-8. PubMed ID: 26946767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.